TransCelerate, Cognizant To Develop New Trials Collaboration Platform
Non-profit TransCelerate BioPharma and Cognizant Healthcare and Life Sciences announced that the organizations have entered into partnership to build a subscription-based platform for clinical sites and pharmaceutical companies.
Pharmaceutical firms often individually deploy investigator platforms, which result in mixed environments. The ‘Shared Investigator Platform’ will attempt to promote standardization and consistency to clinical trials by bringing clinical sites and sponsors from around the world together on a common platform.
The SIP will offer investigators and staff a central, single-access point to clinical trial data. The partners said the platform may provide regulatory authorities an efficient electronic audit process and greater insight into the trials.
Jackie Kent, Senior Director of Clinical Development Information and Optimization at Eli Lilly & Co., and Shared Investigator Platform Leader at TransCelerate, said, “The Shared Investigator Platform will benefit sites by simplifying processes, and reducing time and effort spent on standard study activities… We anticipate an overall improvement in the quality of studies and the data generated from the Shared Investigator Platform initiative.”
Last month TransCelerate launched two initiatives in R&D called Clinical Data Transparency initiative and Clinical Research Quality Management System initiative. “With the launch of these new projects, we continue to tackle areas of R&D inefficiency and common need,” said Dr. Dalvir Gill, CEO of TransCelerate. The company also appointed two new members to its Board of Directors, namely UCB representative Iris Low-Friedrich and Takuko Yamada-Sawada from Shionogi & Co.
Bhaskar Sambasivan, VP of Cognizant's Life Sciences practice, said, “We are pleased to partner with TransCelerate to build this first-of-a-kind platform, which will help maximize the potential of technology-based collaboration and provide better medicines to patients, greater efficiency to clinical sites, and superior business outcomes to pharmaceutical sponsors. Streamlining the clinical trials process will enable TransCelerate's member companies to not only speed up drug development, but also drive innovation in improving patient health.” Sambasivan said that the company will continue to be open to input from its end consumers to improve the platform.
Founding members of TransCelerate include AbbVie, Eli Lilly, Sanofi, Roche, and Pfizer. Other members include Allergan, Cubist, Biogen Idec, and Forest Laboratories, among others.